Cutting‐edge strategies for borderline resectable pancreatic cancer
Abstract Worldwide, pancreatic ductal adenocarcinoma (PDAC) accounts for more than 400 000 deaths every year, being the 12th most common cancer and the seventh most frequent cause of death from cancer. Regardless of the advances in diagnosis and treatment, PDAC continues to have dismal outcomes and...
Main Authors: | Rajesh S. Shinde, Manish Bhandare, Vikram Chaudhari, Shailesh V. Shrikhande |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | Annals of Gastroenterological Surgery |
Subjects: | |
Online Access: | https://doi.org/10.1002/ags3.12254 |
Similar Items
-
Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition
by: Louisa Bolm, et al.
Published: (2020-04-01) -
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
by: Quisette P. Janssen, et al.
Published: (2020-01-01) -
How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated—A Comprehensive Review
by: Daria Kwaśniewska, et al.
Published: (2023-08-01) -
Extended Venous Resections for Borderline Resectable Pancreatic Head Adenocarcinoma—A Retrospective Studies of Nine Cases
by: Nicolae Bacalbasa, et al.
Published: (2021-07-01) -
Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management
by: Fawaz A, et al.
Published: (2022-12-01)